Table 1.

Summary of melanoma-specific studies eliciting patient-derived health utilities

Author, year	Melanoma population	Source / Elicitation techniques	Health Statea	Utilityb
Beusterien,[78] 2009	Advanced melanoma	Standard gamble	Clinical response states
			Partial response	0.88
			Stable disease	0.80
			Progressive disease	0.52
			Best supportive care	0.52
Dixon,[21] 2006	Stage III	EQ-5D	Treatment with Interferon	0.76
			Controls	0.79
Crott,[73] 2004	Stage III	Time trade- off	Treatment with Interferon	0.52
			Recurrence	0.23
Kilbridge,[79] 2001	Early stage melanoma	Standard gamble	Interferon with no side effects	0.92
			Interferon with mild-moderate side effects	0.88
			Interferon with laboratory side effects	0.86
			Interferon with severe side effects	0.81
			Interferon, recurrence	0.62
			Recurrence	0.61
			Disease free survival	0.96
Chen,[80] 2004	Stages I, II, III	Time trade- off	Stage I (Actual / Hypothetical)	0.93 / 0.94
			Stage II (Actual / Hypothetical)	0.97 / 0.73
			Stage III (Actual / Hypothetical)	0.52 / 0.50
FACT-M validation study		EQ-5D	Stage I	0.90
			Stage II	0.87
			Stage III	0.82
			Stage IV	0.82

Abbreviations: EQ-5D, EuroQol EQ-5D

^aThe health states presented in this table do not reflect the entirety of health states estimated in these studies.

^bWhen separate utility coefficients were estimated for multiple time points, the earliest time point was presented.